AzTrials
AzTrials

Extremely Premature InfantHumidITINCT06399861

Humidity in Incubators for Tiny Infants

A study testing Higher (90%) starting RH in the incubator with humidity supplementation stopped at day 10, Lower (70%) starting RH in the incubator with humidity supplementation stopped at day 10 and Higher (90%) starting RH in the incubator with humidity supplementation stopped at day 28 in people with Extremely Premature Infant, run by The University of Texas Health Science Center, Houston at 9 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The objective of the study is to compare different supplemental incubator humidification strategies for infants <25 weeks' gestation admitted to the neonatal intensive care unit (NICU). Read more about this study

Who is it for?
Ages 0 days to 1 day
Conditions the study is for
Extremely Premature Infant
What is being tested?
Higher (90%) starting RH in the incubator with humidity supplementation stopped at day 10, Lower (70%) starting RH in the incubator with humidity supplementation stopped at day 10 and Higher (90%) starting RH in the incubator with humidity supplementation stopped at day 28
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
900 participants
Where
9 sitesUnited States
Study dates
25 Jun 2024to 1 Jun 2030
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 0 days to 1 day
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Inborn infant of <25 weeks' gestation admitted to the neonatal intensive care unit (NICU)

Who cannot join

  • Infants with known congenital skin conditions
  • Outborn infants
  • Infants with unknown gestational age prior to birth
  • Infants with redirection of intensive care prior to study enrollment
  • Infants whose parents request not to participate

Trial locations and contacts

9 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Matthew A. Rysavy, MD, PhD contact

713-500-5651

Matthew.A.Rysavy@uth.tmc.edu

9 sites in 1 country

United States9 sites, 9 recruiting
  • The University of Alabama at Birmingham

    Birmingham, Alabama, 35294

    Colm Travers, MD, cptravers@uabmc.edu

    Colm Travers, MD

    Recruiting
  • Nationwide Children's Hospital - Grant Medical Center

    Columbus, Ohio, 43205

    Carl Backes, MD, 614-722-2000, Carl.Backes@nationwidechildrens.org

    Carl Backes, MD

    Recruiting
  • Nationwide Children's Hospital - Ohio State University Wexner Medical Center

    Columbus, Ohio, 43210

    Carl Backes, MD, 614-293-8000, Carl.Backes@nationwidechildrens.org

    Carl Backes, MD

    Recruiting
  • Children's Memorial Hermann Hospital

    Houston, Texas, 77030

    Matthew A. Rysavy, MD, PhD, 713-500-5651, Matthew.A.Rysavy@uth.tmc.edu

    Matthew Rysavy, MD

    Recruiting
  • Texas Children's Hospital

    Houston, Texas, 77030

    Shweta Parmekar, MD, Shweta.Parmekar@bcm.edu

    Shweta Parmekar, MD

    Recruiting
  • The Woman's Hospital of Texas

    Houston, Texas, 77054

    Kaashif Ahmad, MD, kahmad@uh.edu

    Kaashif Ahmad, MD, Mac

    Recruiting
  • St. Luke's Baptist Hospital

    San Antonio, Texas, 78229

    Christine Aune, MD, 210-297-5000, Christine_Aune@mednax.com

    Christine Aune, MD

    Recruiting
  • North Central Baptist Hospital

    San Antonio, Texas, 78258

    Brent Reyburn, MD, 210-297-4000, brent.reyburn@pediatrix.com

    Brent Reyburn, MD

    Recruiting
  • Sharp Mary Birch Hospital for Women & Newborns

    San Diego, California, 92123

    Rachelle Sey, PhD, CNS, RNC-NIC, Rachelle.Sey@sharp.com

    Katherine Coughlin, MD, katherine.coughlin@sharp.com

    Recruiting

Other trials in United States

About this study

Official title: Humidity in Incubators for Tiny Infants (HumidITI) Trial

The objective of the study is to compare different supplemental incubator humidification strategies for infants <25 weeks' gestation admitted to the neonatal intensive care unit (NICU). The study aims to compare higher (90%) and lower (70%) starting relative humidity (RH), as well as shorter (10 days) and longer (28 days) duration of humidity supplementation.

Being tested
Higher (90%) starting RH in the incubator with humidity supplementation stopped at day 10, Lower (70%) starting RH in the incubator with humidity supplementation stopped at day 10, Higher (90%) starting RH in the incubator with humidity supplementation stopped at day 28, Lower (70%) starting RH in the incubator with humidity supplementation stopped at day 28
Keywords
Humidification Protocol

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Higher (90%) starting RH in the incubator with humidity supplementation stopped at day 10Device

    Infants will be provided usual delivery room care and then placed in an incubator on admission to the NICU, receiving starting relative humidity (RH) of 90% in the incubator, which is weaned to 50% by day 8, and humidity supplementation stopped at day 10.

  • Lower (70%) starting RH in the incubator with humidity supplementation stopped at day 10Device

    Infants will be provided usual delivery room care and then placed in an incubator on admission to the NICU, receiving starting relative humidity (RH) of 70% in the incubator, which is weaned to 50% by day 8, and humidity supplementation stopped at day 10.

  • Higher (90%) starting RH in the incubator with humidity supplementation stopped at day 28Device

    Infants will be provided usual delivery room care and then placed in an incubator on admission to the NICU, receiving starting relative humidity (RH) of 90% in the incubator, which is weaned to 50% by day 8, and humidity supplementation stopped at day 28.

  • Lower (70%) starting RH in the incubator with humidity supplementation stopped at day 28Device

    Infants will be provided usual delivery room care and then placed in an incubator on admission to the NICU, receiving starting relative humidity (RH) of 70% in the incubator, which is weaned to 50% by day 8, and humidity supplementation stopped at day 28.

Study groups in NCT06399861
Study groupRoleWhat they receive
Higher (90%) starting RH in the incubator with humidity supplementation stopped at day 10Active comparatorInfants will be provided usual delivery room care and then placed in an incubator on admission to the NICU, receiving starting relative humidity (RH) of 90% in the incubator, which is weaned to 50% by day 8, and humidity supplementation stopped at day 10.
Receives: Device: Higher (90%) starting RH in the incubator with humidity supplementation stopped at day 10
Lower (70%) starting RH in the incubator with humidity supplementation stopped at day 10Active comparatorInfants will be provided usual delivery room care and then placed in an incubator on admission to the NICU, receiving starting relative humidity (RH) of 70% in the incubator, which is weaned to 50% by day 8, and humidity supplementation stopped at day 10.
Receives: Device: Lower (70%) starting RH in the incubator with humidity supplementation stopped at day 10
Higher (90%) starting RH in the incubator with humidity supplementation stopped at day 28Active comparatorInfants will be provided usual delivery room care and then placed in an incubator on admission to the NICU, receiving starting relative humidity (RH) of 90% in the incubator, which is weaned to 50% by day 8, and humidity supplementation stopped at day 28.
Receives: Device: Higher (90%) starting RH in the incubator with humidity supplementation stopped at day 28
Lower (70%) starting RH in the incubator with humidity supplementation stopped at day 28Active comparatorInfants will be provided usual delivery room care and then placed in an incubator on admission to the NICU, receiving starting relative humidity (RH) of 70% in the incubator, which is weaned to 50% by day 8, and humidity supplementation stopped at day 28.
Receives: Device: Lower (70%) starting RH in the incubator with humidity supplementation stopped at day 28

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Composite safety score

    A single composite safety score will be reported (mortality and 6 morbidities will be assessed to determine this score). The composite score ranges from 0 to 7, with a higher score indicating a better outcome, as listed below:

    • 0 = Infant does not survive
    • 1 = Infant survives, has all 6 assessed morbidities
    • 2 = Infant survives, has 5 assessed morbidities
    • 3 = Infant survives, has 4 assessed morbidities
    • 4 = Infant survives, has 3 assessed morbidities
    • 5 = Infant survives, has 2 assessed morbidities
    • 6 = Infant survives, has 1 assessed morbidities
    • 7 = Infant survives, has no assessed morbidities

    Morbidities assessed:

    • grade III-IV intraventricular hemorrhage (IVH)
    • surgical necrotizing enterocolitis (NEC) or focal intestinal perforation (FIP)
    • grade III bronchopulmonary dysplasia (BPD)
    • treated retinopathy of prematurity (ROP)
    • culture-proven late-onset sepsis (LOS)
    • patent ductus arteriosus (PDA) ligation

    Measured: from admission to the NICU through hospital discharge (about 4-5 months)

Secondary outcomes (21)
  1. Average axillary temperatures in degrees Celsius (°C)

    Measured: daily from admission to the NICU to day 28

  2. Average daily total fluid intake in milliliters per kilogram per day (mL/kg/d)

    Measured: daily from admission to the NICU to day 28

  3. Average daily total fluid output in milliliters per kilogram per day (mL/kg/d)

    Measured: daily from admission to the NICU to day 28

  4. Average daily weight in grams

    Measured: daily from admission to the NICU to day 28

  5. Average daily serum sodium in milliequivalents per liter per day (mEq/L/d)

    Measured: daily from admission to the NICU to day 28

  6. Highest serum creatinine level in in mg/dL

    Measured: from admission to the NICU to postnatal day 28

  7. Average daily calories administered in kilocalories per kilogram per day (kcal/kg/d)

    Measured: daily from admission to the NICU to day 28

  8. Average daily protein administered in grams per kilogram per day (g/kg/d)

    Measured: daily from admission to the NICU to day 28

  9. Number of participants who were administered insulin

    Measured: from admission to the NICU to postnatal day 28

  10. Number of participants who were administered vasopressor

    Measured: from admission to the NICU to postnatal day 28

  11. Number of unplanned removals of vascular access or breathing tube

    Measured: from admission to the NICU to postnatal day 28

  12. Weight in grams

    Measured: 36 weeks postmenstrual age

  13. Length in centimeters

    Measured: 36 weeks postmenstrual age

  14. Head circumference in centimeters

    Measured: 36 weeks postmenstrual age

  15. Number of participants who survive to hospital discharge

    Measured: from admission to the NICU to discharge (about 4-5 months)

  16. Number of participants with severe (grade III-IV) intraventricular hemorrhage (IVH)

    Measured: from admission to the NICU to discharge (about 4-5 months)

  17. Number of participants with surgical necrotizing enterocolitis (NEC) or focal intestinal perforation (FIP)

    Measured: from admission to the NICU to discharge (about 4-5 months)

  18. Number of participants with grade III bronchopulmonary dysplasia (BPD)

    Measured: from admission to the NICU to discharge (about 4-5 months)

  19. Number of participants with treated retinopathy of prematurity [ROP]

    Measured: from admission to the NICU to discharge (about 4-5 months)

  20. Number of participants with culture-proven late-onset sepsis (LOS)

    Measured: from admission to the NICU to discharge (about 4-5 months)

  21. Number of participants with patent ductus arteriosus (PDA) ligation

    Measured: from admission to the NICU to discharge (about 4-5 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 May 2024
  2. Study start25 Jun 2024
  3. Primary completion15 Jan 2030 (estimated)
  4. Study completion1 Jun 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
900 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06399861
Sponsor's protocol ID
HSC-MS-24-0206
Acronym
HumidITI
Status last verified
Sep 2026
First submitted
26 Apr 2024
Last updated
11 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Higher (90%) starting RH in the incubator with humidity supplementation stopped at day 10, Lower (70%) starting RH in the incubator with humidity supplementation stopped at day 10 and Higher (90%) starting RH in the incubator with humidity supplementation stopped at day 28 in people with Extremely Premature Infant, run by The University of Texas Health Science Center, Houston at 9 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 9 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Matthew A. Rysavy, MD, PhD (713-500-5651, Matthew.A.Rysavy@uth.tmc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Composite safety score (time frame: from admission to the NICU through hospital discharge (about 4-5 months)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in